Home / Financial Report / March 7 Market Close: GovCon Index Up, US Stock Markets Down

March 7 Market Close: GovCon Index Up, US Stock Markets Down

Executive Mosaic’s GovCon Index reversed it’s four day losing streak to close up 0.000% to 93.000. Even with the US stocks posting it third lose in the past four days the GovCon Index was able to remain in the positive.

GovCon Index advancers split evenly with decliners as seven of its 11 S&P 500 components advanced with Raytheon (NYSE:RTN) posting in the top five up $1.15 to $154.47.

Healthcare shares lead the decline with Trump promising to lower drugs prices in the U.S.

Market Summary

Index Value Net Change % Change
GovCon Index 93.001 +0.037 +0.040%
S&P 500 2,368.38 -6.93 -0.29%
Dow Jones Industrial Average 20,924.76 -29.58 -0.14%
NASDAQ 5,833.93 -15.25 -0.26%
Advancing GovCon Index Issues 16
Declining GovCon Index Issues 14
Unchanged GovCon Index Issues 0

Top GovCon Index Net Performers

Symbol Company $ Current Price Net Change ▴ % Change
LMT Lockheed Martin * 268.96 +1.24 +0.46%
ICFI ICF 42.15 +1.15 +2.80%
RTN Raytheon * 154.47 +1.15 +0.75%
BA Boeing * 182.00 +1.07 +0.59%
NOC Northrop Grumman * 243.76 +0.84 +0.35%

Top GovCon Index Percentage Performers

Symbol Company $ Current Price Net Change % Change ▴
ICFI ICF 42.15 +1.15 +2.80%
VEC Vectrus 22.10 +0.55 +2.55%
KBR KBR 14.59 +0.13 +0.90%
RTN Raytheon* 154.47 +1.15 +0.75%
BAH Booz Allen Hamilton 36.17 +0.23 +0.64%

GovCon Index Decliners

Symbol Company $ Current Price Net Change ▾ % Change
MCK McKesson Corp. * 147.30 -2.94 -1.96%
NAV Navistar 24.86 -1.27 -4.86%
CACI CACI Intern. 123.05 -0.60 -0.49%

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.